Viewing Study NCT01105832


Ignite Creation Date: 2025-12-24 @ 9:56 PM
Ignite Modification Date: 2025-12-30 @ 6:32 PM
Study NCT ID: NCT01105832
Status: COMPLETED
Last Update Posted: 2014-12-10
First Post: 2010-04-13
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Does Teriparatide (rhPTH 1-34) Promote Fracture Healing in Proximal Humeral Fractures?
Sponsor: University Hospital, Linkoeping
Organization:

Study Overview

Official Title: Påskyndar PTH läkningen av Konservativt Behandlade Humerusfrakturer?
Status: COMPLETED
Status Verified Date: 2014-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: 40 postmenopausal women, with a non-operated proximal humeral fracture, will be randomized to standard treatment (physiotherapy) or standard treatment + Forsteo (rhPTH 1-34) during 4 weeks. Follow-up will be at 7 weeks and 3 months including x-ray and DASH score (The Disabilities of the Arm, Shoulder and Hand) measuring physical function, and pain on a visual analoge scale (VAS).

Two doctors, blinded to the treatment, will judge the callus formation and healing on the x-rays and guess the treatment. The DASH score and the pain score will be compared between the treatment groups.

The investigators hypotheses are that callus formation and healing will be more pronounced and that patients have less pain and better function in the rhPTH 1-34 group.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: